PALO ALTO, Calif. — Silicon Valley and the Bay Area have transformed commerce, technology, communications, and other fields, while also playing an outsized role in biomedical research. Can they find a formula to similarly disrupt and radicalize health care?

Part of the answer depends on public trust of tech giants. Part depends on the Food and Drug Administration, and how it might regulate data-driven products, such as artificial intelligence diagnostic tools that are becoming central to medical practice and drug development.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • If you want a health sector desperately in need of disruption and innovation, try dentistry. The profession is rooted in conflicts of interest with its professional association also having commercial and trade roles, defending the use of dated and dangerous products on which it held patents, adding a gag order to its code of ethics, keeping its practice, insurance and records wholly separate from health care in the U.S., fighting the introduction of mid level providers, etc.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy